People are asking if being immunosuppressed is associated with COVID-19 risk and /or COVID-19 severity of illness. With schools reopening, another important question is focused on transmission of SARS-CoV-2 from and to children, and how to minimize these risks. AHS’ COVID-19 Scientific Advisory Group (SAG) recently summarized the latest evidence from around the world pertaining to key questions:
And, with schools reopening, what role might children play in community SARS-CoV-2 transmission and how might we mitigate risk of transmission?
As Alberta reduces public health restrictions as part of its relaunch strategy, the risk of COVID-19 transmission increases. Evidence so far shows that risk in schools is highly linked to the prevalence of community transmission. Children are more likely to be asymptomatic or mildly ill, and child to adult transmission is comparatively low in data to date, so school reopening is reasonable if community transmission is controlled, and reasonable precautions are in place. A summary of recommendations around school reopening is presented.
In addition, although data on immunosuppressed individuals is somewhat limited, elevated risk appears mainly confined to those on active cancer therapies, on higher doses of steroids and potentially those with uncontrolled autoimmune disease. People on many of the immunomodulating drugs do not, so far, appear to have higher COVID-19 risk. Actual risk to immunosuppressed patients may be underestimated due to the high degree of precautions these patients have taken in their day-to-day lives since the start of the pandemic.
Recommendations arising from the immunosuppressed state review:
- Immunosuppressed patients should continue close adherence to measures such as distancing, hand and respiratory hygiene.
- Immunosuppressed patients should continue their prescribed disease therapy, unless otherwise directed by their healthcare provider.
- Patients on systemic steroids should not abruptly discontinue corticosteroid use. However, healthcare providers should consider additional disease-modification therapy, where necessary, to successfully taper steroid use (to the lowest possible dose without risking a disease flare), with a goal to achieve disease control and reduce possible excess risk of COVID-19 infection and severity.
- Since age and some comorbidities are associated with severe COVID-19 outcomes, individual assessment of immunosuppressed patients should, whenever possible, include risk of recognized and severe outcomes, taking into account age, underlying illness, co-morbidities and chronic therapy (including corticosteroid use).
The recommendations within the school reopening report are available here. To see the complete list of Rapid Response Reports, please check the COVID-19 Scientific Advisory Group website. New reports and updates appear here on a daily basis.
Related NewsAll News & Events
September 20, 2023
Siksika Nation and CPSA Sign Historic Memorandum of Understanding
At this historic point in time, there is a mutual recognition of the autonomy and self-government of Siksika Nation (“Siksika”) and CPSA’s regulatory authority over physicians and physician assistants practicing in Siksika, and the adoption of measures to address systemic racism in health care. Board Chair, Siksika Health Services: Ike Solway Chair, CPSA Council: Stacey...
Indigenous Health, Media Release, Partners
June 14, 2023
CPSA, AHS & AMA launch micro-aggression training for physicians
The College of Physicians & Surgeons of Alberta (CPSA), Alberta Health Services (AHS) and the Alberta Medical Association (AMA) have worked in partnership for several months to develop a micro-aggression training course for Alberta’s physicians. Racism and discrimination are unacceptable in any setting. In healthcare, racism and discrimination leads to negative care experiences for patients,...
CPSA, From the Registrar, Partners, Physicians